NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
IDBI Bank Q3 FY26 Net Profit at ₹1,935 Cr; Gross NPA Improves to 2.57%
IDBI Bank reported a marginal 1% YoY increase in Q3 FY26 net profit to ₹1,935 crore, while 9M FY26 profit surged 39% to ₹7,570 crore, aided by a stake sale in NSDL. Asset quality continues to be a strong point, with Gross NPA declining by 100 bps YoY to 2.57% and Net NPA remaining stable at 0.18%. Loan growth was healthy at 15% YoY, though Net Interest Margin (NIM) compressed to 3.52% from 5.17% in the previous year's quarter, which had been boosted by a one-time tax refund interest. The bank maintains an exceptionally strong capital position with a CRAR of 24.63%.
முக்கிய அம்சங்கள்
Net Profit for Q3 FY26 stood at ₹1,935 crore, while 9M FY26 profit reached ₹7,570 crore including ₹1,699 crore from NSDL stake sale.Gross NPA ratio improved significantly to 2.57% from 3.57% YoY; Net NPA remains low at 0.18% with a PCR of 99.33%.Net Advances grew 15% YoY to ₹2,38,786 crore, with a retail-to-corporate mix of 71:29.Capital Adequacy Ratio (CRAR) strengthened to 24.63%, up from 21.98% in the previous year.CASA ratio stood at 44.06%, though it saw a decline from 46.35% recorded in December 2024.
👀 கவனிக்க வேண்டியவை
Investors should view the continued improvement in asset quality and robust capital adequacy as strong indicators of stability. While NIMs have normalized after previous one-offs, the bank's healthy credit growth and low Net NPA make it a solid performer in the mid-sized banking space.
Bhartiya International Incorporates New Step-Down Subsidiary ULTIMA FASHIONS UK LTD in UK
Bhartiya International Limited (BIL) has announced the successful incorporation of a new step-down subsidiary in the United Kingdom. The new entity, named ULTIMA FASHIONS UK LTD, was incorporated on January 16, 2026. It is a wholly owned subsidiary of Ultima SA, which is an existing subsidiary of BIL. This move follows the company's initial proposal disclosed on January 15, 2026, and signifies a strategic push to expand its footprint in the UK market.
முக்கிய அம்சங்கள்
Incorporation of ULTIMA FASHIONS UK LTD as a wholly owned subsidiary of Ultima SA.The new entity was officially registered in the United Kingdom on January 16, 2026.Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015.Strategic expansion of the company's international fashion business operations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's future updates regarding the scale of operations and capital investment in this new UK unit. This expansion could lead to better revenue diversification in the long term.
Bhartiya International to Incorporate UK Step-Down Subsidiary with GBP 50,000 Investment
Bhartiya International Limited (BIL) has announced the incorporation of a new step-down wholly owned subsidiary in the United Kingdom through its subsidiary, Ultima SA. The new entity will focus on the Textile and Apparel business to support the company's operations in the UK market. The initial investment is capped at GBP 50,000, comprising 5,000 ordinary shares at a face value of GBP 10 each. This move indicates a strategic push to strengthen the company's direct presence in the European region.
முக்கிய அம்சங்கள்
Incorporation of a 100% step-down wholly owned subsidiary in the United Kingdom.Initial investment not exceeding GBP 50,000 divided into 5,000 ordinary shares.The entity will operate in the Textile and Apparel sector to support UK business operations.The expansion is being executed through Ultima SA, an existing wholly owned subsidiary of BIL.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward international market consolidation, though the small initial investment suggests a lean operational start. Monitor future revenue contributions from the UK segment to gauge the success of this expansion.
Biocon Limited has successfully raised Rs 4,150 crore (~USD 460 million) through a Qualified Institutions Placement (QIP) by issuing 11.26 crore shares at Rs 368.35 per share. The primary purpose of this fundraise is to finance the buyout of Viatris' (Mylan Inc.) stake in Biocon Biologics and to repay debt associated with this acquisition and Edelweiss CCDs. This strategic move will make Biocon Biologics a 100% wholly owned subsidiary by March 31, 2026. The QIP attracted 39 institutional investors, including major names like SBI Mutual Fund, ICICI Prudential, and JPMorgan.
முக்கிய அம்சங்கள்
Raised Rs 4,150 crore through the issuance of 112,664,585 equity shares at Rs 368.35 each.Funds will be used to acquire the remaining minority stake in Biocon Biologics from Viatris.Aims to repay debt incurred for the acquisition of Biocon Biologics shares and Edelweiss CCDs.The integration of Biocon Biologics as a wholly owned subsidiary is expected by March 31, 2026.Strong institutional participation from 39 domestic and international investors.
👀 கவனிக்க வேண்டியவை
The successful fundraise and move to 100% ownership of the biologics business is a significant positive for long-term value unlocking. Investors should monitor the impact of debt reduction and the operational integration of the biologics unit on future earnings.
Biocon Allots 11.27 Crore Equity Shares via QIP to Raise ₹4,150 Crore
Biocon Limited has successfully completed a Qualified Institutional Placement (QIP), raising ₹41,500 million (₹4,150 crore) to strengthen its financial position. The company allotted 11,26,64,585 equity shares at an issue price of ₹368.35 per share, representing a significant capital infusion. Major institutional investors including SBI Mutual Fund and ICICI Prudential Mutual Fund participated heavily, each taking up nearly 29.5% of the total issue. This fundraise results in an equity dilution of approximately 7.47% as the total share count increases to 162.09 crore shares.
முக்கிய அம்சங்கள்
Allotted 11,26,64,585 equity shares at an issue price of ₹368.35 per shareTotal capital raised through the QIP amounts to ₹41,500 million (₹4,150 crore)Paid-up equity capital increased from ₹754.12 crore to ₹810.45 croreSBI Mutual Fund and ICICI Prudential Mutual Fund emerged as lead allottees, each securing 29.5% of the issueThe placement was completed within a two-day window from January 12 to January 14, 2026
👀 கவனிக்க வேண்டியவை
Investors should factor in the ~7.5% equity dilution on future EPS while noting the strong institutional backing and improved liquidity for the company. Monitor management commentary regarding the specific utilization of these funds, likely for debt reduction or biosimilar growth initiatives.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Biocon Closes QIP Raising Approx ₹4,150 Crore at ₹368.35 Per Share
Biocon Limited has successfully concluded its Qualified Institutions Placement (QIP) which opened on January 12, 2026. The company's Fund Raising Committee approved the allocation of 11,26,64,585 equity shares to eligible institutional buyers. The issue price was finalized at ₹368.35 per share, representing a total fundraise of approximately ₹4,150 crore. This capital infusion is expected to strengthen the company's balance sheet and support its strategic growth initiatives.
முக்கிய அம்சங்கள்
Allocation of 11,26,64,585 equity shares of face value ₹5 each to qualified institutional buyers.Issue price fixed at ₹368.35 per share, which includes a premium of ₹363.35.The final price represents a 5% discount to the regulatory floor price of ₹387.74 per share.The fundraise was completed within a three-day window from January 12 to January 14, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step for capital adequacy, though they should account for the equity dilution. Monitor management's commentary on the specific utilization of these funds, particularly regarding debt reduction in the biosimilars segment.
Aditya Birla Money Q3 PAT at ₹14.22 Cr; Revenue Up 12% QoQ to ₹119.58 Cr
Aditya Birla Money reported a sequential recovery in Q3 FY26 with a Profit After Tax (PAT) of ₹14.22 crore, up 40% from the previous quarter, though it remains 35% lower than the ₹21.81 crore reported in the same quarter last year. Revenue from operations grew 12.3% QoQ to ₹119.58 crore, driven by growth in both Broking and Wholesale Debt Market segments. The company recognized an exceptional charge of ₹3.13 crore due to the implementation of new Labour Codes. Despite the QoQ improvement, operating margins contracted significantly to 15.24% compared to 28.73% in the year-ago period.
முக்கிய அம்சங்கள்
Revenue from operations increased 11.5% YoY and 12.3% QoQ to ₹119.58 crore.Net Profit (PAT) stood at ₹14.22 crore, showing 40.2% growth over Q2 FY26 but a 34.8% decline YoY.Broking segment revenue grew to ₹92.13 crore, while Wholesale Debt Market revenue rose to ₹26.71 crore.Operating margins declined to 15.24% from 28.73% in the previous year's corresponding quarter.An exceptional item of ₹3.13 crore was recorded for statutory impacts related to new Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin compression and the impact of the new labor codes on long-term employee costs. While sequential growth is positive, the year-on-year decline in profitability suggests rising competitive pressures.
Rubicon Research Expands to Saudi Arabia with New Subsidiary AdvaGen S A
Rubicon Research Limited has successfully incorporated a wholly owned subsidiary, AdvaGen S A Company, in the Kingdom of Saudi Arabia as of January 13, 2026. The new entity is established with an initial share capital of SAR 1,00,000, consisting of 100 equity shares at a face value of SAR 1,000 each. This move marks the company's strategic entry into the Saudi Arabian pharmaceutical market to deal in various pharma products. The investment is a 100% cash consideration, ensuring full control by Rubicon Research.
முக்கிய அம்சங்கள்
Incorporation of AdvaGen S A Company in Saudi Arabia as a 100% wholly owned subsidiaryInitial subscription cost of SAR 1,00,000 for 100 equity sharesThe subsidiary will focus on the pharmaceutical industry and product dealingStrategic geographic expansion into the Middle Eastern healthcare marketNo governmental or regulatory approvals were required for the incorporation
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward geographic diversification and market expansion. Monitor the subsidiary's future performance and its ability to scale operations in the GCC region.
A B Infrabuild Secures ₹55.26 Crore Railway Project from East Coast Railways
A B Infrabuild Limited has been awarded a domestic contract worth approximately ₹55.26 crore by East Coast Railways. The project involves the construction of a Road Over Bridge (ROB) in the Khurda Road Division, specifically between Jhadupudi and Sompeta Railway stations. The company is expected to complete the project within a 24-month timeframe. This new order strengthens the company's infrastructure portfolio and provides revenue visibility for the next two fiscal years.
முக்கிய அம்சங்கள்
Total contract value is ₹55,26,31,365.74 (approx. ₹55.26 Crores)Project awarded by East Coast Railways, Indian Railways, for construction of a Road Over BridgeExecution timeline for the project is 24 monthsProject includes construction of composite and RCCT-Beam girders at Rly. Km. 641/19-21
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that bolsters the order book; focus on the company's ability to maintain margins during the 24-month execution period.
Biocon Approves Interim Financial Statements for H1 FY26 Amid QIP Process
Biocon Limited has released its unaudited condensed consolidated interim financial statements for the six-month period ended September 30, 2025. This disclosure is a procedural requirement following the company's announcement regarding a Qualified Institutions Placement (QIP). The statements provide a comparative analysis against the same period in 2024 and have been reviewed by statutory auditors M/s. B S R & Co. LLP. This filing ensures financial transparency for institutional investors participating in the upcoming fundraise.
முக்கிய அம்சங்கள்
Approval of unaudited condensed consolidated interim financial statements for the half-year ended September 30, 2025.Financials include comparative data for the six-month period ended September 30, 2024.Statements prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013.Limited review report issued by statutory auditors M/s. B S R & Co. LLP.Filing supports the ongoing Qualified Institutions Placement (QIP) issue opening.
👀 கவனிக்க வேண்டியவை
Investors should monitor the pricing and size of the QIP as these interim financials provide the basis for institutional valuation. No immediate action is required other than tracking potential equity dilution from the fundraise.
Biocon Subsidiary Receives US FDA Approval for Everolimus Tablets (2mg, 3mg, 5mg)
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received US FDA approval for its ANDA for Everolimus Tablets for Oral Suspension. The approval covers three dosage strengths: 2 mg, 3 mg, and 5 mg, targeting the treatment of Tuberous Sclerosis Complex (TSC). This product is indicated for both adult and pediatric patients, specifically for those with Subependymal Giant Cell Astrocytoma or TSC-associated seizures. This regulatory milestone strengthens Biocon's vertically integrated drug portfolio in the critical US market.
முக்கிய அம்சங்கள்
Received US FDA approval for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths.Indicated for TSC patients with SEGA (aged 1+) and TSC-associated partial-onset seizures (aged 2+).Approval granted to Biocon Pharma Limited, a 100% subsidiary of Biocon Limited.Strengthens the company's portfolio of vertically integrated drug products for international markets.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch timeline and the potential market share Biocon can capture in this niche segment. This approval validates Biocon's R&D capabilities and supports long-term growth in its generics business.
BirlaNu Wins GST Case: Telangana HC Rescinds ₹16.76 Crore Tax and Penalty Demand
BirlaNu Limited (formerly HIL Limited) has received a favourable ruling from the Telangana High Court regarding a long-standing GST dispute. The court rescinded a proposed tax demand of ₹8.38 crore and an equivalent penalty of ₹8.38 crore related to Input Service Distributor (ISD) registration. This order effectively eliminates a total potential liability of approximately ₹16.76 crore. The company confirmed that no tax, interest, or penalty is now payable in this specific matter, strengthening its financial position.
முக்கிய அம்சங்கள்
Telangana High Court rescinded a GST demand of ₹8.38 croreA penalty of ₹8.38 crore previously proposed has been entirely droppedTotal financial relief for the company amounts to approximately ₹16.76 croreThe dispute originated from the company's Input Service Distributor (ISD) registration methodologyThe order was received on January 7, 2026, following a decision dated December 30, 2025
👀 கவனிக்க வேண்டியவை
This is a positive outcome that clears a potential financial liability from the company's books. Investors should view this as a resolution of legal risk, though it does not fundamentally change the core business operations.
A B Infrabuild Secures ₹54.26 Crore Railway Project from East Coast Railways
A B Infrabuild Limited has secured a new contract from East Coast Railways for the construction of a Road Over Bridge (ROB) on the HWH-VSKP Main Line. The project, valued at approximately ₹54.26 Crore, involves the construction of composite and T-beam girders. This domestic order is scheduled for completion within a 24-month period. The win reinforces the company's presence in the railway infrastructure segment.
முக்கிய அம்சங்கள்
Awarded a ₹54.26 Crore contract by East Coast Railways for bridge construction.Project involves building a Road Over Bridge (ROB) with composite and T-beam girders.Execution timeline for the project is 24 months from the date of acceptance.The contract is located in the Khurdha Road Division on the HWH-VSKP Main Line.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for the company's order book and future revenue visibility. Monitor the execution progress over the 24-month timeline to ensure margins are maintained.
Panacea Biotec Completes Phase III Enrollment for DengiAll Vaccine with 10,335 Participants
Panacea Biotec has achieved a major milestone by completing the enrollment of 10,335 participants for the Phase III clinical trials of DengiAll, India's first indigenous single-shot dengue vaccine. The trial, conducted in collaboration with ICMR, will now move into a two-year monitoring phase to evaluate the vaccine's efficacy and immunogenicity. This development keeps the company on track for a projected market entry by 2027. Successful commercialization would address a significant unmet medical need in tropical regions, potentially creating a substantial long-term revenue stream.
முக்கிய அம்சங்கள்
Completed enrollment of 10,335 study participants for Phase III clinical trials of DengiAll vaccine.DengiAll is positioned as India's first indigenous single-shot tetravalent dengue vaccine candidate.Two-year monitoring period initiated to examine long-term efficacy and immunogenicity post-administration.Commercial market launch is anticipated by 2027 following the completion of the observation period.Project is being executed in collaboration with the Indian Council of Medical Research (ICMR).
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook on the company's R&D pipeline as this milestone reduces execution risk. However, since commercialization is expected only by 2027, this remains a long-term play with interim clinical data being the next key catalyst.
Biocon to Expand Oncology Portfolio with Keytruda & Opdivo Biosimilars; Integration by March 2026
Biocon Biologics is expanding its oncology portfolio with three major biosimilars targeting drugs with combined 2024 sales exceeding $40 billion, including Keytruda and Opdivo. The company is on track to integrate Biocon Biologics as a wholly owned subsidiary by March 31, 2026, to streamline operations and focus on high-growth areas like GLP-1 peptides and insulins. This strategic move targets a $75 billion oncology market opportunity, representing 35% of the global pharmaceutical market. Post-integration, Shreehas Tambe will lead the combined entity as CEO & Managing Director.
முக்கிய அம்சங்கள்
Unveiling biosimilars for Keytruda ($29.5B sales), Opdivo ($9.3B), and Herceptin SC ($1.72B)Oncology portfolio now includes 17 assets, targeting an addressable market of over $75 billionFull integration of Biocon Biologics into Biocon Ltd expected to be completed by March 31, 2026Strategic focus on Diabetes, Oncology, and Immunology, which comprise 40% of global pharma revenue
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the corporate integration and the regulatory filing timelines for the high-value oncology biosimilars. The combined focus on GLP-1 peptides and biosimilar insulins positions the company well for the growing global metabolic health market.
A B Infrabuild Secures Rs 10.75 Crore EPC Road Project in Madhya Pradesh
A B Infrabuild Limited has been awarded a new contract by the M.P. Road Development Corporation Ltd for road infrastructure work. The project involves constructing additional lanes for truck parking and lay byes on the NH-30 stretch in Madhya Pradesh. Valued at Rs 10.75 crore, the contract will be executed on an EPC (Engineering, Procurement, and Construction) basis. The project is expected to be completed within a short timeframe of 9 months, which could lead to rapid revenue recognition.
முக்கிய அம்சங்கள்
New project award worth Rs 10.75 crore from M.P. Road Development Corporation Ltd.Project involves construction of truck parking lanes on the Mangawan to MP-UP border section of NH-30.Execution timeline is set at 9 months, indicating a fast-track project cycle.The contract is awarded on an EPC mode, ensuring the company handles design and construction.No promoter or group company interest involved, ensuring a standard commercial transaction.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive addition to the company's order book, providing revenue visibility for the next three quarters. Monitor the company's ability to execute within the 9-month deadline to maintain margins.
Biocon Consolidates Biocon Biologics Stake to 94% via Share Swap and USD 200M Cash
Biocon Limited has significantly increased its ownership in its subsidiary, Biocon Biologics Limited (BBL), to approximately 94% on a fully diluted basis. The transaction involved acquiring 26.19 crore BBL shares through a share swap, issuing 17.12 crore new Biocon shares at Rs. 405.78 each to partners including Mylan and Serum Institute. Additionally, the company completed a cash acquisition of 7.18 crore BBL shares from Mylan for USD 200 million. While this consolidates a high-growth asset, it results in an 11.36% equity dilution for existing Biocon shareholders.
முக்கிய அம்சங்கள்
Acquired 33.37 crore total shares of Biocon Biologics, taking ownership to ~94% on a fully diluted basisIssued 17.12 crore new equity shares at a preferential price of Rs. 405.78 per sharePaid USD 200 million in cash to Mylan as part of a larger USD 400 million acquisition agreementPost-allotment, Mylan Inc. and Serum Institute hold 6.10% and 3.68% stakes in Biocon Ltd respectivelyTotal paid-up equity capital increased from 133.69 crore shares to 150.82 crore shares
👀 கவனிக்க வேண்டியவை
Investors should view the consolidation of the biologics arm as a strategic positive for long-term valuation, though they must factor in the 11% equity dilution. Monitor the company's debt profile following the USD 200 million cash payout.
Biocon Limited has completed a significant consolidation of its subsidiary, Biocon Biologics Limited (BBL), by acquiring shares from Mylan, Serum Institute, and other partners. The company allotted 17.13 crore equity shares at an issue price of Rs. 405.78 per share, resulting in an 11.36% equity dilution. Additionally, Biocon paid USD 200 million in cash to Mylan for a portion of the stake. Following these transactions, Biocon's ownership in its high-growth biologics arm has increased to approximately 94% on a fully diluted basis.
முக்கிய அம்சங்கள்
Allotted 17,12,79,553 equity shares at Rs. 405.78 per share on a preferential basis.Acquired 26.19 crore BBL shares via share swap and 7.18 crore BBL shares for USD 200 million cash.Biocon's total holding in Biocon Biologics Limited (BBL) increased to approximately 94%.Post-allotment, Mylan Inc. holds 6.10% and Serum Institute holds 3.68% in Biocon Limited.Total paid-up equity share capital increased from 133.70 crore to 150.82 crore shares.
👀 கவனிக்க வேண்டியவை
Investors should note the consolidation of the biologics business as a long-term positive for control and simplified structure, though they must account for the 11.36% equity dilution. Monitor the performance of Biocon Biologics as it now represents a much larger portion of the parent's value.
Biocon Completes Early Redemption of Rs 500 Crore NCDs
Biocon Limited has successfully completed the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). The total value of the redemption amounts to Rs 500 Crores, with each NCD having a face value of Rs 1,00,000. The payment was executed on January 05, 2026, following Board approval granted in November 2025. This early repayment indicates a strong liquidity position and will likely reduce the company's future interest expenses.
முக்கிய அம்சங்கள்
Early full redemption of 50,000 unlisted, secured, rated NCDs completed.Total redemption amount aggregates to Rs 500 Crores.Face value per NCD was Rs 1,00,000, originally issued in May 2023.Payment completed on January 05, 2026, ahead of the January 31, 2026 target date.
👀 கவனிக்க வேண்டியவை
The early debt repayment is a positive indicator of Biocon's balance sheet strength and cash management. Investors should view this as a move to optimize capital structure and reduce interest costs.
IDBI Bank Q3 FY26 Update: Net Advances Grow 15% YoY to ₹2.38 Lakh Crore
IDBI Bank has released its provisional business updates for the quarter ended December 31, 2025, showing a 12% YoY growth in total business to ₹5,46,634 crore. Net advances grew robustly by 15% YoY to reach ₹2,38,806 crore, indicating strong credit momentum. Total deposits increased by 9% YoY to ₹3,07,828 crore, though CASA deposits saw a slight sequential decline from ₹1,39,036 crore in September 2025 to ₹1,35,630 crore in December 2025. Overall, the bank maintains a steady growth trajectory in its core lending and deposit base.
முக்கிய அம்சங்கள்
Total Business grew 12% YoY to ₹5,46,634 crore as of December 31, 2025Net Advances increased by 15% YoY to ₹2,38,806 crore from ₹2,06,807 croreTotal Deposits rose 9% YoY to ₹3,07,828 crore compared to ₹2,82,439 crore in the previous yearCASA deposits stood at ₹1,35,630 crore, reflecting a 3.6% YoY growth but a 2.4% sequential decline
👀 கவனிக்க வேண்டியவை
Investors should view the strong credit growth positively, but monitor the slight dip in CASA and its impact on the cost of funds in the upcoming full earnings report. The stock remains a watch for further updates on the bank's privatization process alongside these operational improvements.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
